Board to consider Dividend
Merck Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 24, 2017, inter alia, to consider and approve the audited financial results for the year ended December 31, 2016 and to consider recommendation of dividend for the year 2016. Shareholding for the Period Ended December 31, 2016
Merck Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Merck Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Merck Gets Demand Notice From Regulator For Overcharging
Merck said the government has issued the demand notice despite the fact that the company was neither a manufacturer nor a marketer of the subject drug. Demand Notice from NPPA (National Pharmaceutical Pricing Authority)
Merck Ltd has informed BSE that the Company has received a demand notice from National Pharmaceutical Pricing Authority (NPPA) demanding a sum of Rs. 11.68 crores plus interest Rs. 15.78 crores alleging overcharging of price of the formulation, Polybion L 100 ML syrup, during the period from January 2006 to June 2009. The government has issued the demand notice despite the fact that the Company was neither a manufacturer nor a marketer of the subject... Updates on Appointment of Director
With reference to earlier letter dated December 23, 2016 submitted to Stock Exchange regarding appointment of Ms. Zoe Tang as the Non- Executive Director of the Company and with reference to clarification/information sought by National Stock Exchange on dated December 23, 2016, Merck Ltd has now submitted herewith brief profile of Ms. Zoe Tang as required.Further this is to confirm that Ms. Zoe Tang is not related to any of the Directors of the Company. Appointment of Director
With reference to the earlier letter dated October 04, 2016 about the nomination of Ms. Zoe Tang, (also known as Mei Lin Tang) by Merck KGaA, Merck Ltd has now informed BSE that Ms. Zoe Tang has been appointed as the Non- Executive Director of the Company effective December 23, 2016. Closure of Trading Window
Merck Ltd has informed BSE that the Company has already issued notification to its employees on December 12, 2016 regarding closure of trading window for them for the purposes of consideration and approval of the audited financial results from December 16, 2016 until 48 hours from the publication of the audited financial results for the quarter/year to be ended on December 31, 2016. The Company would be subsequently informing the date of the Board... Standalone Financial Results, Limited Review Report for September 30, 2016
Merck Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Standalone Limited Review for the period ended September 30, 2016 Germany's Merck mull over sale of biosimilar drug business: Sources
Merck's biosimilars business could be worth as much as $1 billion because of its long-term sales potential.